Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2-3 cancer

前列腺活检中神经周围浸润的定量分析可改善活检分级为 2-3 级癌症的风险分层。

阅读:1

Abstract

OBJECTIVE: Perineural invasion (PNI) detected on prostate needle biopsy is a well-established indicator of adverse pathology, while the prognostic role of PNI quantification has recently been suggested. We herein aimed to determine whether PNI quantification could universally stratify risks by separately assessing subgroups of patients based on biopsy Grade Group (GG). METHODS: We quantified actual PNI foci in the entire systematic sextant biopsy specimens from 840 men, including 580 (69.0%) exhibiting no PNI and evaluated long-term oncologic outcomes following radical prostatectomy. RESULTS: PNI was detected in 1 (n = 177; 21.1%), 2 (n = 48; 5.7%) or 3-6 (n = 35; 4.2%) of 6 biopsy sites/parts, while 1 (n = 156; 18.6%), 2 (n = 53; 6.3%) or 3-10 (n = 51; 6.1%) PNI foci were present on each biopsy. In the entire cohort, we confirmed a significantly higher risk of biochemical recurrence in patients with PNI (vs. no PNI; P < 0.001), multi-site PNI (vs. single-site PNI; P < 0.001) or multifocal PNI (vs. unifocal PNI; P < 0.001). In subgroup analyses, significant differences in the risk of postoperative recurrence between the absence vs. presence of PNI were observed only in patients with GG3 or GG4 cancer. In contrast, the prognostic distinction between single-site vs. multi-site PNI or unifocal vs. multifocal PNI was evident in patients with GG2 or GG3 cancer, but not in those with GG1 or GG4-5 cancer. In multivariable analysis, multifocal PNI, but not multi-site PNI, was independently associated with worse recurrence-free survival in the GG2 (hazard ratio 5.866, P = 0.004) and GG3 (hazard ratio 2.716, P = 0.021) groups. Meanwhile, PNI on prostatectomy was confirmed in 98.1% of biopsy PNI-positive cases but was still detected in 72.2% of biopsy PNI-negative cases. CONCLUSION: Quantification of actual PNI foci across all systematic biopsy sites may provide valuable prognostic information, particularly in patients with GG2-3 cancer. Notably, the mere presence of biopsy PNI may not universally predict poorer outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。